表4. コメットアッセイphaseIV-2バリデーション結果
遺伝毒性発癌物質

Chemical (CASRN)	Vehicle	Lab judge	VMT judge	Final judge	Note	
					In vivo genotoxicty	Other information
2-Acetylaminofluorene (53-96-3)	Corn oil	Negative	No change	Negative	UDS, MN, Comet, TG (L): +	Ames, CA: + Rat Carc.: L, Mgl, Ski
Acrylonitrile (107-13-1)	Corn oil	Negative (within historical control range)	Equivocal (Trend: L), Decrease (S)	Positive (L)	UDS, MN, TG: - Comet: +	Ames, CA: + Rat Carc.: Zy, Nrv, Orc. Smi, S, Mgl, Nas
		Negative (within historical control range)	Increase (L)			
o-Anisidine (90-04-0)	Corn oil	Negative	No change	Negative	UDS, MN: - Comet, TG (Ubl): +	Ames, CA: + Rat Carc.: Kid, Thy, Ubl
Azidothymidine (30516-87-1)	0.5% CMC	Positive	Increase (L), Equivocal (Trend:S)	Positive (L)	MN: +	Ames: -, CA: + Rat Carc.: Vag
Benzene (71-43-2)	Corn oil	Negative	No change	Negative	MN, Comet: + TG (L): -	Ames: -, CA: + Rat Carc.: Zy, Nas, Orc, Ski, S, Vsc
Buslfan (55-98-1)	Corn oil	Negative	No change	Negative	MN, Comet: +	Ames, CA: + Mouse Carc.: Hmo, Ova
Cadmium chloride (10108-64-2)	Saline	Positive	Increase (L), Equivocal (Du: S)	Positive (L)	MN: + or - Comet: -	Ames: -, CA: + Rat Carc.: Hmo, Kid, Lun, Pro, Tes
p-Chloroaniline (106-47-8)	Corn oil	Positive	Increase (L, S)	Positive (L, S)	MN: equivocal Comet: +	Ames: +, CA: + or - Rat Carc.: Spl
Cisplatin (15663-27-1)	0.5% CMC	Positive	Increase (L)	Positive (L)	MN, Comet, TG (L): +	Ames, CA: +
2,4-Diaminotoluene (95-80-7)	Saline	Equivocal	Increase (L)	Positive (L)	UDS, TG (L): + MN, Comet: + or -	Ames, CA: + Rat Carc.: L, Mgl
		Positive	Increase (L)			
1,2-Dibromoethane (106-93-4))	Corn oil	Positive	Increase (L, S)	Positive (L, S)	UDS, Comet: + MN, TG (L): -	Ames, CA: + Rat Carc.: Nas, Per, Pit, S, Vsc, L, Lun, Mgl
1,3-Dichloropropene (542-75-6)	Corn oil	Positive	Increase (L)	Positive (L)	UDS, MN: - Comet: +	Ames, CA: + Rat Carc.: L
Chemical	Vehicle	Lab judge	VMT judge	Final	Note	

(CASRN)				judge	*In vivo* genotoxicty	Other information
1,2-Dimethylhydrazine 2HCl (306-37-6)	Saline	Positive	Increase (L)	Positive (L)	UDS, MN, Comet: +	Ames, CA: + Rat Carc: not available Mouse Carc.: Lung, Vsc
		Positive	Increase (L)			
Hydroquinone (123-31-9)	Saline	Negative	No change	Negative	MN: + (aneugen)	Ames: -, CA: + Rat Carc.: Kid, Hmo
Methyl methanesulfonate (66-27-3)	Saline	Positive	Increase (L, S)	Positive (L, S)	UDS, MN, Comet: + TG: + or -	Ames, CA: + Mouse Carc.: Hmo, Lun
N-Nitrosodimethylamine (62-75-9)	Saline	Positive	Increase (L)	Positive (L)	UDS, MN, Comet: +	Ames, CA: + Rat Carc.: L, Kid, Lun, Tes, Vsc
		Positive	Increase (L)			
4,4'-Oxydianiline (101-80-4)	0.5% CMC	Negative	Decrease (S)	Negative	UDS: - MN, Comet: +	Ames, CA: + Rat Carc.: L, Thy
Sodium arsenite (7784-46-5)	Saline	Positive	Equivocal (Trend: L)	Equivocal	MN: +	Ames: -, CA: + Rat Carc.: not available Mouse Carc: L
		Negative	Equivocal (Dunnett: L)			
Thioacetamide (62-55-5)	Saline	Negative (due to toxicity)	Increase (L, S)	Positive (S)	MN, Comet: +	Ames, CA: - Rat Carc.: L Hepatotoxicant

遺伝毒性非発癌物質

Chemical (CASRN)	Vehicle	Lab judge	VMT judge	Final judge	Note	
					In vivo genotoxicty	Other information
9-Aminoacridine hydrochloride monohydrate (52417-22-8)	Corn oil	Negative	No change	Negative	No data	Ames: +
p-Anisidine (104-94-9)	0.5% CMC	Negative	No change	Negative	No data	Ames, CA: +
2,6-Diaminotoluene (823-40-5)	Corn oil	Positive	Increase (L)	Positive (L)	UDS, MN, Comet: + or -	Ames, CA: +
5-Fluorouracil (51-21-8)	Saline	Negative	No change	Negative	MN: + Comet: -	Ames, CA: -
8-Hydroxyquinoline (148-24-3)	Corn oil	Negative	Decrease (S)	Negative	UDS, MN, Comet: -	Ames, CA: +
p-Phenylenediamine dihydrochloride (624-18-0)	Saline	Negative	No change	Negative	MN, Comet: -	Ames, CA: +

非遺伝毒性発癌物質

Chemical (CASRN)	Vehicle	Lab judge	VMT judge	Final judge	Note	
					In vivo genotoxicty	Other information
Chloroform (67-66-3)	Corn oil	Negative (due to toxicity)	Increase (L)	Negative	UDS, Comet, TG (L): - MN: + or -	Ames, CA: - Rat Carc.: Kid, L Hepatotoxicant
Diethanolamine (111-42-2)	Saline	Negative	No change	Negative	MN: -	Ames, CA: - Rat Carc: - Mouse Carc. (dermal): L
Di(2-ethylhexyl)phthalate (117-81-7)	Corn oil	Negative	No change	Negative	UDS, MN, Comet, TG: -	Ames, CA: - Rat Carc.: L Peroxisome proliferator
Ethanol (64-17-5)	Saline	Negative	No change	Negative	MN: -	Ames, CA: - Rat Carc.: Adr, L, Pan, Pit Hepatotoxicant
Methyl carbamate (598-55-0)	Saline	Negative	No change	Negative	MN: -	Ames, CA: - Rat Carc.: L Hepatotoxicant
Saccharin (81-07-2)	Corn oil	Negative	No change	Negative	MN, TG (L): - Comet: +	Ames, CA: - Rat Carc.: Ubl
o-Phenylphenol sodium salt (132-27-4)	Corn oil	Negative	No change	Negative	MN, CA: - Comet: + or -	Ames: - CA: + or - Rat Carc.: Kid, Ubl

非遺伝毒性非発癌物質

Chemical (CASRN)	Vehicle	Lab judge	VMT judge	Final judge	Note	
					In vivo genotoxicty	Other information
Ampicillin trihydrate (7177-48-2)	Saline	Negative	Equivocal (Trend:L)	Negative	MN: -	Ames: -, CA: +
	Corn oil	Negative	No change			
o-Anthranilic acid (118-92-3)	0.5% CMC	Negative	No change	Negative	MN: -	Ames: - CA: +
t-Butylhydroquinone (1948-33-0)	Corn oil	Negative (within historical control range)	Increase (L), Equivocal (Du: S)	Positive (L)	MN: -	Ames: - CA: +
Ethionamide (536-33-4)	Corn oil	Negative	Decrease (S)	Negative	No data	Ames: - CA: +
Isobutyraldehyde (78-84-2)	Corn oil	Negative	No change	Negative	MN: -	Ames: - CA: +
D,L-Menthol (15356-70-4)	Corn oil	Negative	No change	Negative	MN, Comet: -	Ames: - CA: +
Sodium chloride (7647-14-5)	Water	Negative	Decrease (S)	Negative	CA: - UDS (S): -	Ames, CA: - Gastrotoxicant
Trisodium EDTA monohydrate (10378-22-0)	Saline	Negative	No change	Negative	Comet: -	Ames, CA: -

G. 研究発表

1. 論文発表

1) 小島肇夫：動物実験代替法の現状と展望、J.Environ Dermatol Cutan Allergol,3（1）、1-6（2009）

2) 小島肇夫：動物実験の3Rsにおける国内外の動向、城西大学生命科学研究センター報告第7号、p37-50（2009）

3) 小島肇夫：動物実験データなしで新規医薬部外品の申請はどこまで可能か？、BIO INDUSTRY,26（8）42-49（2009）

4) 小島肇夫：皮膚・粘膜毒性、新版　トキシコロジー、日本トキシコロジー学会教育委員会編集、pp.246-254（2009）

5). 小島肇夫：医薬部外品と化粧品、GLP/非GLP試験の具体的実施ポイント、技術情報、東京、pp.425-433（2009）

6) 小島肇夫：REACHにおける環境影響試験、フレグランスジャーナル　2009-8、46-51（2009）

7) 小島肇夫、新井晶子、北條麻紀：再構築培養表皮モデルを用いた遺伝毒性の評価、コスメトロジー研究報告、17、57-62（2009）

8) 小島肇夫：現在の動物実験代替法の状況について、LABIO21、38、17-20（2009）

9) 小島肇夫：薬用化粧品の承認取得における安全性試験をめぐる問題点、医薬部外品有効成分承認取得のための対策と課題、フレグランスジャーナル社、48-58（2010）

10) 小島肇夫：医薬部外品の製造販売承認申請における安全性試験の資料に関するあり方検討会報告、日皮協ジャーナル、印刷中（2010）

11) Kojima, H.: Commentary to the Discussion on Topics 3, " In Vitro Test Approaches with Bettre Predictivity" at the 5th International Workshop on GenotoxicityTesting, Genes and Environment,32(2), 40-42 (2010)

12) 小島肇夫：総合評価の方法、有用性化粧品の処方とその活用、鈴木正人監修、シーエムシー出版、東京、pp.147-151　(2010)

13) Kojima, H, Takeyosh,i M, Sozu, T, Awogi, T, Arima, K, Idehara, K, Ikarashi, Y, Kanazawa, Y, Maki, E, Omori, T, Yuasa, A, Yoshimura, I.:Inter-laboratory validation of the modified murine local lymph node assay based on 5-bromo-2'-deoxyuridine incorporation.J Appl Toxicol. 31(1)63-74 (2010)

14) Yamamoto, N, Hirano, K, Kojima, H, Sumitomo, M, Yamashita, H, Ayaki, M, Taniguchi, K, Tanikawa, A, Horiguchi, M.: Cultured human corneal epithelial stem/progenitor cells derived from the corneal limbus. In Vitro Cell Dev Biol Anim. 46(9):774-80 (2010)

15) Kojima, H.: 3Rs Activities in Japan, AVLR8 Alternative Testing strategies, Progress report 2010, 266 (2010)

16) 小島肇夫：パイロジェン試験、大阪医薬品協会　会報第745号31-63（2011）

17)小島肇夫：動物実験代替法の現状と展望、創薬研究のストラテジー、pp.41-48、株式会社金芳堂、京都（2011）

18)小島肇夫：動物実験の3Rにおける国内外の動向、ドージンニュースNo.138、1-9（2011）

19)柘植英哉、森充生、大庭澄明、大内正、寺田三郎、五島隆志、田邊豊重、山影康次、田中憲穂、渡辺美香、畔上二郎、大向英夫、小島肇：平成21年度「日本薬局方の試験法に関する研究」研究報告、輸液用ゴム栓試験法の見直し（第3報）ー細胞毒性試験法の検討ー、医薬品医療機器レギュラトリーサイエンス42（3）258-271（2011）

20) 小島肇夫：動物実験代替法における国際協調、日薬理誌、138、103-107（2011）

21) 小島肇夫：経皮吸収と安全性、次世代経皮吸収型製剤の開発と応用、pp.157-164、シーエムシー出版、東京（2011）

22) 小島肇夫：監修及び序章、動物実験代替法と動物実験の住み分け、pp.3-9、第1章第2節　日本における各種承認申請に必要な安全性試験と代替法の受理の現状、pp.19-23、第1章第3節　REACH.GHSなどの各種規制との違い、pp.24-29、第2章　皮膚腐食性試験の実験手法、pp.33-43、第4章　眼刺激性試験代替法の実験手法、pp.71-87、最新　動物実験代替法の技法ノウハウ、技術情報協会、東京（2011）

23) 小島肇夫：第8回国際動物実験代替法会議参加記、COSME　TECH　JAPAN,1（5）：29-33（2011）

24) 小島肇夫：技術講座　安全性評価試験（1）、COSME　TECH　JAPAN, 1（6）：10-13（2011）

25) Pfuhler S, Fellows M, van Benthem J, Corvi R, Curren R, Dearfield K, Fowler P, Frötschl R, Elhajouji A, Le Hégarat L, Kasamatsu T, Kojima H, Ouédraogo G, Scott A, Speit G: In vitro genotoxicity test approaches with better predictivity: Summary of an IWGT workshop, Mutat. Res., 723(2):101-7 (2011)

26) 小島肇夫：技術講座　安全性評価試験（2）、COSME　TECH　JAPAN,1（7）：18-22（2011）

27) Kano, S., Todo, H., Furui, K., Sugie, K., Tokudome, Y., Hashimoto, F., Kojima, H., Sugibayashi, K.: Comparison of Several Reconstructed Cultured Human Skin Models by Microscopic Observation: Their Usefulness as an

Alternative Membrane for Skin in Drug Permeation Experiments, Altern. Animal Test. EXperiment, 16(2): 51-58（2011）

28) 小島肇夫：技術講座　安全性評価試験（3）、COSME TECH JAPAN、2(1) ：73-77(2012)

29) 小島肇夫：技術講座　安全性評価試験（4）、COSME TECH JAPAN、2(2)：65-69(2012)

30) 小島肇夫：技術講座　安全性評価試験（5）、COSME TECH JAPAN、2(3)：44-49 (2012)

31）Kojima, H., Ando, Y., Idehara, K., Katoh, M., Kosaka, T., Miyaoka, E., Shinoda, S., Suzuki, T., Yamaguchi, Y., Yoshimura, I., Yuasa, A., Watanabe, Y. and Omori, T. : Validation Study of the *In Vitro* Skin Irritation Test with the LabCyte EPI-MODEL24, Altern Lab Anim., 40, 33-50 (2012)

2.学会発表

1) 小島　肇：バリデーション研究とは何か？&国際動向、JaCVAM第2回ワークショップ、東京（2009）

2) 小島　肇：培養皮膚モデルバリデーション研究、JaCVAM第2回ワークショップ、東京(2009)

3) 小島　肇：動物実験代替法に関する国内外の動向、JALAMシンポジウム「安全性試験における動物実験代替法－国内外の動向と代替法開発の現状－」、大宮（2009）

4) 小島　肇：動物実験代替法における培養細胞の利用：合同追悼シンポジウム「黒田行昭先生を偲んで」、日本組織培養学会第82回大会、栃木（2009）

5) 小島　肇：バリデーション試験の今後の予定について、コメットアッセイ国際バリデーション試験進捗報告、日本環境変異原学会　MMS研究会　第54回定例会、熱川（2009）

6) 小島　肇、安藤洋子、山口能宏、小坂忠司、鈴木民恵、湯浅敦子、渡邉幸彦、篠田伸介、出原賢治、吉村　功、宮岡悦良、石山賢也、加藤雅一、大森　崇：培養皮膚モデル LabCyte EPI-MODEL24 を用いた皮膚刺激性試験代替法のバリデーション研究、第 36 回日本トキシコロジー学会学術年会、盛岡(2009)

7) 小島　肇:OECD Test Guideline収載モデルとしてのLabCyte EPI-MODLの可能性、皮膚基礎研究クラスターフォーラム、東京（2009）

8) Kojima, H.：3D comet assay, JaCVAM experience, 5th International Workshop on Genotoxicity Testing, Basel (2009)

9) Kojima, H., Yamakage, K., Burlinson, B., Escobar, P., Pant, K., Kraynak, A., Hayashi, M., Corvi, R., Uno, Y., Schechtman, L., Tice, R. and Honma, M.: International validation study of the in vitro alkaline comet assay, 8th International Comet Assay Workshop, Perugia (2009)

10) Nakajima, M., Masumori, S., Tanaka, J., Hayashi, M., Uno, Y., Kojima, H. and Tice, R.: An atlas of comet images: JaCVAM initiative International Validation trial for the in vivo comet assay, 8th International Comet Assay Workshop, Perugia (2009)

11) Kojima, H. : Validation of innovative methods for safety testing: drawbacks and advantages of Japanese validation studies, 7th World Congress on Alternatives & Animal Use in the Life Sciences, Rome（2009）

12) Kojima, H., Matsui, T., Kohara, A., Yoshida, A. and Nakamura, Y.: GCCP initiatives in Japan, 7th World Congress on Alternatives & Animal Use in the Life Sciences, Rome（2009）

13) Ono, A., Takeyoshi, M., Bremer, S., Jacob, M., Laws, S., Sozu, T. and Kojima, H.: The International validation study for the ER alpha STTA antagonist assay using HeLa9903, 7th World Congress on Alternatives & Animal Use in the Life Sciences, Rome（2009）

14) Allen, D., Deal, F., Ceger, P., Gordon, J., Pazos, P., deLange, L., Bremer, S., Nakamura, M., Kojima, H., Ono, A., Tice, R. and Stokes W.: Testing of coded substances for a multi-phases international validation study of an estrogen receptor (ER) transcriptional activation (TA) assay, 7th World Congress on Alternatives & Animal Use in the Life Sciences, Rome（2009）

15) Kojima, H., IIjima, M., Matsunaga, K., Sasa, H., Itagaki, H., Okamoto, Y., Nishiyama, N., Mita I., Washida, J., Masuyama, K., Onodera, H., Masuda, M., Ohno, Y.: Review of an alternative to animal testing for safety evaluation of cosmetic ingredients using Quasi-drug, 7th World Congress on Alternatives & Animal Use in the Life Sciences, Rome（2009）

16) Wind, M., Blakey, D., Kojima, H., Kreysa, J. and Stokes, W.: What is the international cooperation on alternative test methods (ICATM) and what is its role?, 7th World Congress on Alternatives & Animal Use in the Life Sciences, Rome（2009）

17) Kojima, H. : JaCVAM's role in the 3Rs and ICATM, 7th World Congress on Alternatives & Animal Use in the Life Sciences, Rome（2009）

18) Kojima, H. : Recent progress and future directions at JaCVAM, 7th World Congress on Alternatives & Animal Use in the Life Sciences, Rome（2009）

19) Inoue, T., Masuda, M., Akita. M., Kojima, H. and Ohno, Y.: JaCVAM statement on new alternative to animal testing, 7th World Congress on Alternatives & Animal Use in the Life Sciences, Rome（2009）

20) Takeyoshi, M., Kojima, H., Omori, T., Sozu, T. and

Yoshimura, I.: Validation study for non-radioisotopic local lymph node assay based on BrdU incorporation (LLNA-BrdU), 7th World Congress on Alternatives & Animal Use in the Life Sciences, Rome (2009)

21) Kojima, H., Ando Y., Yamaguchi Y., Kosaka T., Suzuki T., Yuasa A., Watanabe Y., Shinoda S., Idehara K., Yoshimura I., Miyaoka E., Ishiyama K., Kato M., Omori T. : Validation of LabCyte EPI-MODEL24, an *In Vitro* Assay for Detecting Skin Irritants, 7th World Congress on Alternatives & Animal Use in the Life Sciences, Rome (2009)

22) Yamamoto, N., Hirano, K., Kato, M., Hata, K., Horiguchi, M., Taniguchi, K. and Kojima, H.: Cell surface maker of corneal epithelium stem cells and culture, 7th World Congress on Alternatives & Animal Use in the Life Sciences, Rome (2009)

23) Lowther, D., Wind, M., Stokes, W., Barroso, J., Zuang, V., Amcoff, P., Kojima, H., Prinsen, M., Tice, R., Allen, D. and McCall, D.: International acceptance of in vitro alternative ocular safety testing methods: the isolated chicken eye (ICE) test method (Draft OECD TG 438), 7th World Congress on Alternatives & Animal Use in the Life Sciences, Rome (2009)

24) Merrill, J., Wind, M., Stokes, W., Barroso, J., Zuang, V., Amcoff, P., Kojima, H., Jacobs, A., McCall, D. Allen D. and Tice, R.,: International acceptance of in vitro alternative ocular safety testing methods: bovine corneal opacity and permeability (BCOP) test method (Draft OECD TG 437), 7th World Congress on Alternatives & Animal Use in the Life Sciences, Rome (2009)

25) Hayashi, M., Uno, Y., Honma, M., Schectmann, L., Tice, R., Corvi, R., Morita, T., Asano, N. and Kojima, H.: In vivo Comet Assay: Update on the on-Going international validation study, 7th World Congress on Alternatives & Animal Use in the Life Sciences, Rome (2009)

26) Honma, M., Kojima, H., Morita, T., Uno, Y., Asano, N., Nakajima, M., Corvi, R., Tice, R., Schectman, L. and Hayashi, M.: International validation study of the in vitro alkaline comet assay, 7th World Congress on Alternatives & Animal Use in the Life Sciences, Rome (2009)

27) Kojima, H., Arai S. and Hojo M.: Adequate conditions for performance of comet assay using 3-dimensional human epidermal model, 7th World Congress on Alternatives & Animal Use in the Life Sciences, Rome (2009)

28) Stokes, W., Wind, M., Matheson, J., Jacob., A., Casati, S., Kojima, H., Allen, D., Burns, T., Salicru, E., Strickland, J. and Tice, R., Internationally harmonized performance standards (PS) for the murine local lymph node assay (LLNA), 7th World Congress on Alternatives & Animal Use in the Life Sciences, Rome (2009)

29) Honma, M., Kojima, H., Morita, T., Uno, Y., Asano, N., Nakajima, M., Corvi, R., Tice, R., Schechtman, L. and Hayashi, M.: International validation study of the in vitro alkaline comet assay, 25th ICEM , Florence (2009)

30) Uno, Y., Kojima, H., Honma, M., Schechtman, L., Tice, R., Corvi, R., Morita, T., Asano, N. and Hayashi, M.,: In vivo Comet Assay: Update on the on-Going international validation study, 25th ICEM , Florence (2009)

31) 小島　肇：動物実験代替法における国内外の動向、日本薬学会関東支部大会、埼玉（2009）

32) 小島　肇：In vitro 安全性・機能性評価及び作用メカニズム・新規物質探索研究の最前線 、第22回動物細胞工学シンポジウム、東京（2009）

33) 小島　肇：医薬部外品の承認申請における安全性に関する資料のあり方検討会、日本産業皮膚衛生協会　秋季研修会、京都（2009）

34) Kojima, H.: Japanese views in the 3Rs in the 21st century, ZEBET's 20th Anniversary Symposium, Berlin, Germany (2009)

35) Kojima, H.: Organization of JaCVAM and its activity, KoCVAM International Symposium and 6th Congress of KSAAE, Seoul (2009)

36) Kojima, H.: Utilization of an alternative to animal testing for safety evaluation of cosmetic ingredients using Quasi-drug, The 17th ICDS (International Contact Dermatitis Symposium) and the 10th APEODS (Asia-Pacific Environmental and Occupational Dermatology Symposium), Kyoto (2009)

37) Kojima, H.: Japanese approach to regulatory acceptance of new skin sensitization testings with considerations to animal welfare and 3Rs, The 17th ICDS (International Contact Dermatitis Symposium) and the 10th APEODS (Asia-Pacific Environmental and Occupational Dermatology Symposium), Kyoto (2009)

38) 小島　肇、安藤洋子、山口能宏、小坂忠司、鈴木民恵、湯浅敦子、渡邉幸彦、篠田伸介、出原賢治、吉村　功、宮岡悦良、石山賢也、加藤雅一、大森崇：培養皮膚モデル LabCyte EPI-MODEL24 を用いた皮膚刺激性試験代替法のバリデーション研究、第22回日本動物実験代替法学会総会・学術大会、大阪（2009）

39) 小島　肇、飯島正文、松永佳世子、佐々　斉、板垣　宏、岡本裕子、西山直宏、小野寺博志、見田　活、鷲田　淳、益山光一、増田光輝、大野泰雄：医薬部外品の承認申請における安全性に関わる資料のあり方検討委員会報告、第22回日本動物実験代替法学会総会・学術大会、大阪（2009）

40) 小島　肇、井上　達、増田光輝、秋田正治、

大野泰雄：動物実験代替法公定化のためのJaCVAM提案書、第22回日本動物実験代替法学会総会・学術大会、大阪（2009）

41) 小野　敦、武吉正博、Susanne　Bremer、Miriam Jacob、Susan C. Laws、寒水孝司、小島　肇：HeLa9903細胞を用いたエストロゲン受容体転写活性化試験によるアンタゴニスト検出法の国際バリデーション、第22回日本動物実験代替法学会総会・学術大会、大阪（2009）

42) 本間正充、山影康次、Burlinson, B.、Escobar, P.、Pant, K.、Kraynak, A.、林　真、中嶋圓、鈴木雅也、Corvi, R.、宇野芳文、Schechtman, L.、Tice, R.、小島　肇：In vitroアルカリコメットアッセイ国際バリデーション研究、第22回日本動物実験代替法学会総会・学術大会、大阪（2009）

43) 小島　肇、笠松俊夫：IWGT 報告　トピックス３：予測性の高いin vitro試験の提案、日本環境変異原学会第38回大会、清水・静岡（2009）

44) 中嶋圓、小島　肇、宇野芳文、本間正充、林真：コメットアッセイの国際バリデーション、日本環境変異原学会第38回大会、清水・静岡（2009）

45) 小島　肇、北條麻紀、新井晶子：3次元培養表皮モデルを用いるコメットアッセイと細胞毒性の関係、日本環境変異原学会第 38 回大会、清水・静岡（2009）

46) JaCVAM：コメットアッセイ国際バリデーションプロジェクトチーム：インビボコメットアッセイ：JaCVAM国際バリデーション試験の進捗状況報告、日本環境変異原学会第38回大会、清水・静岡（2009）

47)　伊藤正俊、関東裕美、鷲崎久美子、松永佳世子、矢上晶子、中川真美子、加藤則人、河合恵一、滝脇弘嗣、吉村　功、小島　肇：パッチテストによる皮膚一次刺激性評価（２）、第39回日本皮膚アレルギー・接触皮膚炎学会総会学術大会、京都（2009）

48) 中村昌文、半田洋士、小野 敦、小島 肇：Lumi-cell ERアッセイ法の国際バリデーション(第二報)、第12回環境ホルモン学会研究発表会、東京（2009）

49) 小島　肇、飯島正文、松永佳世子、佐々　斉、板垣　宏、岡本裕子、西山直宏、小野寺博志、見田　活、鷲田　淳、益山光一、増田光輝、大野泰雄：あり方検討会設立の経緯及び動物実験代替法の現状、医薬部外品の製造販売承認申請における安全性に関わる資料のあり方検討委員会報告、東京（2009）

50)　山本直樹、平野耕治、谷川篤宏、加藤雅一、畠賢一郎、小島　肇、綾木雅彦、堀口正之、谷口孝喜：角膜上皮細胞における組織幹細胞マーカーの検索と初代分離培養法及び遺伝子導入法の検討、日本組織培養学会第82回大会、栃木（2009）

51)　山本直樹、平野耕治、谷川篤宏、加藤雅一、畠賢一郎、小島　肇、綾木雅彦、堀口正之、谷口孝喜：角膜上皮細胞の組織幹細胞マーカーと初代分離培養法及び遺伝子導入法の検討、第４１回日本臨床分子形態学会総会・学術集会、神戸（2009）

52)　小島　肇：今後の展望、JaCVAM第3回ワークショップ、h-CLAT シンポジウム、東京（2010）

53)　Kojima, H., Arai, S. and Hojyo, M.: Adequate conditions for performance of comet assay using 3-dimensional human epidermal model, 49th Annual SOT meeting, Salt Lake City (2010)

54)　W Stokes, M Wind,D Blakey, J Kreysa, H Kojima, E Anklam: Establishment of the International Cooperation on Alternative Test Methods (ICATM) and Its Role in the Validation and Regulatory Acceptance of Globally Harmonized Safety Assessment Methods, 49th Annual SOT meeting, Salt Lake City (2010)

55) P Ceger, F Deal, D Allen, G Clark, P Pazos, J de Lange, S Bremer, M Nakamura, H Kojima, A Ono, R Tice, W Stokes, Testing of Coded Substances in the NICEATM/ECVAM/JaCVAM LUMI-CELL® STTA Multiphase International Validation Study, 49th Annual SOT meeting, Salt Lake City (2010)

56) 山本直樹、谷川篤宏、内藤紘策、綾木雅彦、小島　肇、平野耕治、堀口正之：マウス水晶体上皮細胞の不死化細胞の作出、 第114回　日本眼科学会総会（2010.4）

57) 小島　肇：ヒトiPS細胞を用いた新規 *in vitro* 毒性評価系の構築、日本製薬工業協会セミナー（2010.5）

58) 小島　肇：パネルディスカッション　新しい感作性及び局所刺激性（皮膚・眼）試験法のOECDテストガイドライン，日本トキシコロジー学会学術年会，沖縄 (2010.6)

59) 小島　肇：医薬部外品、化粧品のRegulatory Scienceの展望，第11回光老化研究会，東京慈恵会医科大学（2010.7）

60) Kojima.H.： Global impact of 3'Rs on regulatory process: sharing experiences and future trends. XII International Congress of Toxicology, Barcelona, Spain (2010.7)

61) Kojima.H., Inoue, T. and Ohno.Y.: JaCVAM's role of new alternatives to animal testing and international harmonization. XII International Congress of Toxicology, Barcelona, Spain (2010.7)

62) 小島　肇：昨今の国際バリデーション研究の進捗，皮膚基礎研究クラスターフォーラム　第５回教育セミナー (2010.8)

63) 小島　肇：皮膚感作性試験のインビトロ代替法の現状，日本免疫毒性学会学術大会，独立行政法人国立環境研究所　大山記念ホール (2010.9)

64) Kojima, H., Arai, S. and Hojyo M.： Importance of each human model and the optimal protocol for regulatory use of skin irritation assay. The 23rd Annual and International Meeting of the Japanese Association for Animal Cell Technology, Hokkaido University, Sapporo, Japan (2010.9)

65) 小島　肇：パイロジェン試験，大阪医薬品協会技術研究委員会，大阪 (2010)

66) 小島　肇、北條麻紀: 3 次元培養表皮モデルを用いるコメットアッセイの条件検討　第 3 報，日本環境変異原学会第 39 回大会、つくば (2010.11)

67) 宇野芳文、小島　肇：インビボコメットアッセイ　JaCVAM 国際バリデーション試験の進捗状況報告（第 2 報），日本環境変異原学会第 39 回大会、つくば（2010.11）

68)小島　肇、中村　牧、山口能宏、泉　瑠名、鈴木民恵、萩原沙織、篠田伸介、加藤雅一：培養皮膚モデル LabCyte EPI-MODEL24 を用いた皮膚刺激性試験代替法のバリデーション研究、日本動物実験代替法学会第 23 回大会、東京（2010.12）

69)小島　肇、桑原裕史、林卓巳、坂口眞由美、豊田明美、後藤　悠、中村恒彰 、渡辺真一、阿彦恭子 、大森　崇、音泉　卓、寒水孝)、森本隆史、 林　和彦、坂口　斉：眼刺激性試験代替法(STE 試験)バリデーション研究　第 3 報、日本動物実験代替法学会第 23 回大会、東京（2010.12）

70)小島　肇、北條麻紀: 3 次元培養表皮モデルを用いるコメットアッセイの条件検討日本動物実験代替法学会第 23 回大会、東京（2010.12）

71)小島　肇：S5　化学物質の有害性評価に関する代替試験法開発—発癌性、発生毒性、免疫毒性ー今後の展望、日本動物実験代替法学会第 23 回大会、東京（2010.12）

72) 小島　肇：培養皮膚モデルを用いた皮膚刺激性評価の現状、第 10 回ヒューマンサイエンス研究資源バンクセミナー、大阪（2011.1）

73) 小島　肇:動物実験代替法における国際動向、日本動物実験代替法学会・JaCVAM 合同ワークショップ　動物実験の３R における国際動向、東京(2011.2)

74) 小島　肇:皮膚細胞研究の応用とその可能性、日本化粧品技術者会大阪支部　第 15 回勉強会ワークショップ、大阪（2011.2）

75) Kojima, H.: The Japanese Center for the Validation of Alternative Methods (JaCVAM): Recent ICATM contributions and Future Plans, Information Session: The International Cooperation on Alternative Test Methods (ICATM): Translating Science to Provide Improved Public Health Safety Assessment Tools, 50th Annual SOT meeting, Washington D.C.(2011.3)

76) Kojima, H. and Hojyo, M.: Optimal conditions for performance of the comet assay using a three-dimensional human epidermal model, 50th Annual SOT meeting, Washington D.C.(2011.3)

77) W Casey, P Ceger, F Deal, D Allen, G Clark, P Pazos, E Grignard, J de Lange, S Bremer, M Nakamura, H Kojima, A Ono, W Stokes.: Final Results of an International Validation Study of an *In Vitro* ER TA Test Method in BG-1 cells, 50th Annual SOT meeting, Washington D.C.(2011.3)

78) F Deal, W Casey, P Ceger, D Allen, C Yang, M Nakamura, H Kojima, A Ono, HJ Yoon, SY Ha[7], W Stokes:　International Validation Study of an *In Vitro* Cell Proliferation Test Method for Screening Potential Estrogenic Agonists and Antagonists in MCF-7 cells, 50th Annual SOT meeting, Washington D.C.(2011.3)

79) J Kulpa-Eddy, R McFarland, R Isbrucker, M Halder, H Kojima, B Jones, NW Johnson, D Allen, E Lipscomb, S Morefield, W Casey, W Stokes: International Workshop on Alternative Methods to Reduce, Refine, and Replace the Use of Animals in Vaccine Potency and Safety Testing, 50th Annual SOT meeting, Washington D.C.(2011.3)

80) 小島　肇：日本における動物実験代替法の現状、シンポジウム S2H27　アジアにおける動物実験代替法の展開、第 84 回日本薬理学会年会、パシフィコ横浜　(2011.3)

81) 小島　肇：動物実験代替法の行政的受け入れと国際協調、シンポジウム S30　レギュラトリーサイエンスは社会にどう役立っているかー薬学系人材の役割と活躍の場を知るー、日本薬学会第 131 回年会、静岡（2011.3）

82) Kojima,H.: Update of skin equivalent and its regulatory use, BIT's 4th Annual World Congress of Industrial Biotechnology-2011, Dalin, China (2011.4)

83) 小島　肇：安全性評価のための in vitro 試験法を確立するために何をなすべきか、日本組織培養学会第 84 回大会、成育医療センター(2011.5)

84) 山本直樹、平野耕治、小島　肇、住友万里子、山下宏美、中村政志、原　和宏、谷川篤宏、谷口考喜、堀口正之：ヒト角膜組織より分離した

角膜上皮細胞への不死化遺伝子の導入と評価、日本組織培養学会第 84 回大会、成育医療センター（2011.5）

85）小島　肇：医薬品・医療機器の許認可に求められる安全性試験、第 7 回大阪大学医工連携シンポジウム 第 2 回　MEI 産学官連携部門勉強会講演会 大阪大学銀杏会館（2011.6）

86）Yamamoto, N., Hirano, K. , Sumitomo, M., Yamashita, H., Nakamura ,M., Hara , K., Tanikawa , A., Horiguchi, M., Taniguchi K. and Kojima, H. : Generation and Analysis of a New Immortalized Human Corneal Epithelium Cell Line, 2011 In Vitro Biology Meeting, Raleigh, North Carolina, USA(2011.6)

87）Kojima, H.: Current and future of correlation with japan and Korea on alternative to animal experiments, 8th　Congress of Korean Society for Alternative to Animal Experiments, Korea (2011.7)

88）小島　肇：代替法から in vitro toxicology への発想転換、第 38 回日本トキシコロジー学会学術年会、パシフィコ横浜（2011.7）

89）小島　肇：動物実験代替法の申請資料への活用、皮膚基礎研究クラスターフォーラム第 6 回教育セミナー、タワーホール船堀（20011.7）

90）小島　肇：欧米、日本における代替法の現状と化粧品の安全性評価における代替法、千葉科学大学コスメティックサイエンスシンポジウム(第 4 回）、化学会館・F ホール（2011.7）

91）Kojima, H. : Section II-11　The International Cooperation on Alternative Test Methods (ICATM), JaCVAM, 8th World Congress on Alternatives and Animal Use in the Life Sciences, Montreal, Canada (2011.8)

92）Uno, Y., Kojima, H., Hayashi, M.: In vivo Comet assay: update on the ongoing international validation study coordinated by JaCVAM, 8th World Congress on Alternatives and Animal Use in the Life Sciences, Montreal, Canada (2011.8)

93）Kojima ,H., Yamakage, K., Oba, S., Tsuge, H., Aoki, M.: Preliminary study of the revision of Japanese Pharmacopoeia test for rubber closure for aqueous infusions, 8th World Congress on Alternatives and Animal Use in the Life Sciences, Montreal, Canada (2011.8)

94）　Ono, A., Takeyoshi , M., Bremer, S., Jacobs, M., Laws, S., Sozu, T. and Kojima, H.: Results of the validation study of the stably-transfected estrogen receptor alpha transcriptional activation antagonist assay using the HeLa9903 cell line, 8th World Congress on Alternatives and Animal Use in the Life Sciences, Montreal, Canada (2011.8)

95）Hayashi, K., Hayashi, T., Sakaguchi, M., Watanabe, S. and Kojima, H.: Inter-laboratory phase II validation study of in vitro eye irritation test; Short Time Exposure (STE) test, 8th World Congress on Alternatives and Animal Use in the Life Sciences, Montreal, Canada (2011.8)

96）Nakamura, M., Suzuki , T., Shinoda, S., Kato, M. and Kojima, H.: Additional validation of alternative skin irritation test method using LabCyte EPI-MODEL24 of cultured skin, 8th World Congress on Alternatives and Animal Use in the Life Sciences, Montreal, Canada (2011.8)

97）McFarland, R., Kulpa-Eddy, J., Isbrucker, R., Halder, M., Kojima, H., Johnson, N., Jones, B., Allen, D., Casey, W. and Stokes, W.: International workshop　on　alternative methods to reduce, refine, and replace the use of animals in human vaccine potency and safety testing, 8th World Congress on Alternatives and Animal Use in the Life Sciences, Montreal, Canada (2011.8)

98）Kulpa-Eddy , J., McFarland, R., Isbrucker, R., Halder, M., Kojima, H., Johnson, N., Jones, B., Allen, D., Casey, W. and Stokes, W.: International workshop　on　alternative methods to reduce, refine, and replace the use of animals in veterinary vaccine potency and safety testing, 8th World Congress on Alternatives and Animal Use in the Life Sciences, Montreal, Canada (2011.8)

99）Stephens, M., Kojima, H., Patlewicz-Tier, G., Spielmann H. and Telley, L.: AltTox.org: communication platform for 21st century toxicology, 8th World Congress on Alternatives and Animal Use in the Life Sciences, Montreal, Canada (2011.8)

100）Kojima, H.: Necessity of validation study of new or updated test methods for hazard assessment, Workshop on Validation of 3T3 Neutral Red Uptake Phototoxic Test, Guangzhou, China (2011.11)

101）Kojima, H.: JaCVAM update, シンポジウム動物実験代替法センターの国際協調、日本動物実験代替法学会　第 24 回大会、仙台(2011.11)

102）小島　肇：厚生労働省の新規対応、シンポジウム日本における代替法研究の新しい胎動、日本動物実験代替法学会　第 24 回大会、仙台（2011.11）

103）Kojima, H.: JaCVAM update、日本動物実験代替法学会　第 24 回大会、仙台（2011.11）

104）丸山 裕子、湯浅 敦子、日置孝徳、笠原 利彦、小島　肇：LLNA BrdU-ELISA におけるリンパ節細胞懸濁液調製方法の最適化に関する検討、日本動物実験代替法学会　第 24 回大会、仙台（2011.11）

105）篠田伸介、萩原沙織、山口能宏、中村　牧、笠原利彦、芝井亜弥、加藤雅一、小島　肇：

培養表皮モデル LabCyte EPI-MODEL24 皮膚刺激性試験法の追加共同研究、日本動物実験代替法学会　第 24 回大会、仙台（2011.11）

106) 内野　正、竹澤俊明、山下　邦彦、小島　肇、五十嵐良明、西村哲治：ビトリゲルチャンバーを用いた皮膚感作性試験代替法モデルの基礎的検討、日本動物実験代替法学会　第 24 回大会、仙台（2011.11）

107) 山口宏之、竹澤俊明、小島　肇：コラーゲンビトリゲル膜チャンバー内に構築したヒト角膜上皮モデルの有用性：化学物質暴露後の経上皮電気抵抗値の経時変化を指標として眼刺激性を外挿する新しいアプローチ、日本動物実験代替法学会　第 24 回大会、仙台（2011.11）

108) 加藤 義直、山本 直樹、山下 宏美、佐藤 淳、水谷 宏、中田 悟、小島 肇：新規不死化ヒト角膜上皮細胞株（iHCE-NY）を用いた眼刺激性試験代替法への取り組み 、日本動物実験代替法学会　第 24 回大会、仙台（2011.11）

109) 濱田修一、高島理恵、嶋田圭祐、財前和代、川上哲、田中仁、松本浩孝、中井智博、鈴木洋、松村奨士、真田尚和、井上健司、武藤重治、萩尾宗一郎、林亜耶、高柳智美、荻原庸介、前田晃央、成見香瑞範、高沢博修、小川いづみ、大山ワカ子、中嶋圓、森田健、小島肇、林真、本間正充：反復投与肝臓小核試験法の有用性の検討（MMS 共同研究）、日本環境変異原学会第 40 回大会、東京（2011.11）

110) 宇野芳文、小島肇、林真：インビボコメットアッセイ：JaCVAM 国際バリデーション試験の進捗状況報告（第 3 報）、日本環境変異原学会第 40 回大会、東京（2011.11）

111) 中村 昌文、武吉 正博、小野 敦、小島　肇：国際的バリデーションの行われた三種類のエストロゲン様活性測定法の比較検証、環境ホルモン学会、東京(2011.12)

112) 小島　肇：動物実験代替法の国際的動向と JaCVAM 活動について、日本輸入化粧品協会技術部会、東京（2011.12）

113) 小島　肇：毒性発現機序からみたリスク評価の現実　「毒性試験の代替に病理が果たす役割」、第 28 回日本毒性病理学会総会、東京（2012.2）

114) 小島　肇：生物学的製剤基準とワクチンの品質確保にどこまで動物実験は有用か、国際化時代の生物学的製剤基準とワクチンの品質確保のありかた、東京（2012.2）

H. 知的財産権の出願・登録状況
（予定を含む。）

1. 特許取得
なし

2. 実用新案登録
なし

3.その他
なし

J. 添付資料

添付資料 1： Protocol International Validation of the in vivo Rodent Alkaline Comet Assay for the Detection of Genotoxic Carcinogens (Version 14.2)

添付資料 2：phaseIV-Ⅰ　report(draft)

添付資料 3：phaseIV-Ⅱ　report(draft)

添付資料 1

INTERNATIONAL VALIDATION OF THE *IN VIVO* RODENT ALKALINE COMET ASSAY FOR THE DETECTION OF GENOTOXIC CARCINOGENS (VERSION 14.2)

Issued by: the Validation Management Team (VMT)
Date: November 30, 2009 revised

A. PURPOSE OF THIS DOCUMENT

This document is provided to clarify the conduct of an international validation study to evaluate the ability of the *in vivo* rodent alkaline Comet assay to identify genotoxic carcinogens, as a potential replacement for the *in vivo* rodent hepatocyte unscheduled DNA synthesis (UDS) assay. This document represents the final study protocol developed as a result of the collaboration efforts of the participating testing facilities and the VMT. Each testing facility will develop a study protocol based on the information provided in this document.

B. ASSURANCE OF DATA QUALITY

The study will be conducted in facilities that are Good Laboratory Practice compliant. Consistency between raw data and a final report is the responsibility of each testing facility. The VMT may review the data for accuracy, if deemed necessary.

C. ANIMAL WELFARE AND 3Rs

Appropriate national and/or international regulations on animal welfare should be followed. The 3Rs-principle for experimental animal use should be considered for determining the experimental design.

D. TESTING PROCEDURE

1. MATERIALS AND METHODS

1.1. Test substances and positive/negative controls

1.1.1. Test substance

With the exception of ethyl methanesulfonate (EMS), test substances will be supplied to each testing facility by the VMT. When coded substances are supplied, appropriate safety information will be provided in a sealed envelope to be opened only by an appropriate individual within the organization who is not involved in the study and/or in the case of

an emergency. If opened, appropriate documentation and justification will need to be provided to the VMT.

1.1.2. Test substance preparation

Each test substance will be dissolved or suspended with an appropriate solvent/vehicle just before administration (see section 1.1.4.).

1.1.3. Positive control

EMS (CAS No. 62-50-0); the source and lot number to be used will be provided by the VMT. EMS will be dissolved in physiological saline just before administration (within 2 hours).

1.1.4. Negative control (solvent/vehicle)

Solvents/vehicles for test substance preparation will be used as negative controls. An appropriate solvent/vehicle for a test substance may be indicated by the VMT. In the absence of instruction from the VMT, an appropriate solvent/vehicle will be chosen for each test substance by the testing facility in the following order: physiological saline, 0.5% w/v sodium carboxymethylcellulose aqua solution, corn oil.

1.2. Test animals

1.2.1. Species

Although either rats or mice can be used in this assay, the validation study will use rats. The rat is the species most commonly used in toxicological studies and is the preferred species in the *in vivo* rodent hepatocyte UDS assay.

1.2.2. Sex

In order to allow for a direct comparison with the rat hepatocyte UDS assay, males will be used.

1.2.3. Strain

Rat: Crl:CD (SD)

1.2.4. Source

Charles River Laboratories, Inc.

1.2.5. Age

At the time of purchase: 6-8 weeks of age (body weight 150 g - 320 g)

At the time of dosing: 7-9 weeks of age

1.2.6. Body weight

The weight variation of animals should be +/- 20% of the mean weight at the time of

dosing.

1.2.7. Number of animals in each dose group at each sampling time

Five males (see note 1).

1.2.8. Animal maintenance

Animals will be reared under appropriate housing and feeding conditions according to the standard operating procedures (SOP) in each testing facility, consistent with Section C "Animal Welfare".

1.2.8.1. Diet

Animals will be fed *ad libitum* with a commercially available pellet diet.

1.2.8.2. Water

Animals will be given free access to tap water *ad libitum* .

1.2.9. Animal quarantine and acclimation

Animals will be quarantined and acclimated for at least 5 days prior to the start of the study, according to SOPs in each testing facility. Only healthy animals approved by the Study Director and/or the Animal Facility Veterinarian will be used.

1.2.10. Animal identification and group assignment

Animals will be identified uniquely and assigned to groups by randomization on the basis of body weight according to the SOP in each testing facility.

1.3. Preparation of Comet assay solutions

The following solutions will be prepared, consistent with laboratory SOPs, unless otherwise specified (see note 2).

1.3.1. 1.0-1.5% (w/v) standard agarose gel for the bottom layer (if used)

Regular melting agarose will be dissolved at 1.0-1.5% (w/v) in Dulbecco's phosphate buffer (Ca^{++}, Mg^{++} free and phenol free) by heating in a microwave.

1.3.2. 0.5 % (w/v) low-melting agarose (Lonza, NuSieve GTG Agarose) gel for the cell-containing layer and, if used, a top layer

Low-melting agarose will be dissolved at 0.5% (w/v) in Dulbecco's phosphate buffer (Ca^{++}, Mg^{++} free and phenol free) by heating in a microwave. During the study this solution will be kept at 37-45°C and discarded afterward.

1.3.3. Lysing solution

The lysing solution will consist of 100 mM EDTA (disodium), 2.5 M sodium chloride, and 10 mM tris hydroxymethyl aminomethane in purified water, with the pH adjusted to

10.0 with 1 M sodium hydroxide and/or hydrochloric acid. This solution may be refrigerated at <10°C until use. On the same day of use, 1 % (v/v) of triton-X100 and 10 % (v/v) DMSO will be added to this solution and the complete lysing solution will be refrigerated at <10°C for at least 30 minutes prior to use.

1.3.4. Alkaline solution for unwinding and electrophoresis

The alkaline solution consists of 300 mM sodium hydroxide and 1 mM EDTA (disodium) in purified water, pH >13. This solution will be refrigerated at <10°C until use. The pH of the solution will be measured just prior to use.

1.3.5. Neutralization solution

The neutralization solution consists of 0.4 M tris hydroxymethyl aminomethane in purified water, pH 7.5. This solution will be either refrigerated at <10°C or stored consistent with manufacturer's specifications until use.

1.3.6. Mincing buffer

The mincing buffer consists of 20 mM EDTA (disodium) and 10% DMSO in Hank's Balanced Salt Solution (HBSS) (Ca^{++}, Mg^{++} free, and phenol red free if available), pH 7.5 (DMSO will be added immediately before use). This solution will be refrigerated at <10°C until use.

1.3.7. Staining solution

The fluorescent DNA stain is SYBR Gold (Invitrogen-Molecular Probes), prepared and used according to the manufacturer's specifications.

1.4. Comet assay procedure

1.4.1. Experimental design

Compound	Dose (mg/kg/day)	Number of animals (see note 1)
Vehicle (negative control)	0	5
EMS (positive control)	200	5
Test compound	Low (1/4 of high)	5
Test compound	Medium (1/2 of high)	5
Test compound	High*	5

*High dose selection (see note 3): in general, in the absence of VMT directions, the high dose level of a test compound will be selected as the dose producing signs of toxicity such that a higher dose level, based on the same dosing regimen, would be expected to

produce mortality, or an unacceptable level of animal distress. Selection of doses will be based on the toxicity of the test substance but will not exceed 2000 mg/kg/day.

1.4.2. Administration to animals

The test substance will be administered three times orally by gavage, 24 and 21 hours apart, i.e. the second administration is 24 hours after the first administration, and the third administration is 21 hours after the second administration (at 3 hours before animal sacrifice). EMS will be administered twice orally by gavage at 24 hours and 3 hours before animal sacrifice. The administration regimes are summarized in a figure below; this protocol enables us to integrate the comet and micronucleated erythrocyte assay into one assay (see note 4). The dosage volume will be 0.1 mL per 10 g body weight in rats on the basis of the animal weight just before administration.



1.4.3. Measurement of body weight and examination of animal conditions

Individual body weights will be measured in accordance with local SOPs and just prior to administration (the weight at this time will be used to determine the volume of each substance administered) and at the time of termination. The clinical signs of the animals will be observed from just after dosing to just before tissue removal with an appropriate interval according to the SOP in each testing facility.

1.4.4. Tissue sampling

Animals will be humanely killed at 3 hours after third administration of a test substance and at 3 hours after second treatment of EMS, consistent with Section C "Animal Welfare and 3Rs". The stomach and the liver will be removed (see note 5). Tissues will be placed into ice-cold mincing buffer, rinsed sufficiently with the cold mincing buffer to remove residual blood (more rinses would likely be needed if exsanguination is not used), and stored on ice until processed. For histopathology, samples will be obtained from the same

liver lobe, and from a minimal possible area of stomach.

1.4.5. Preparation of single cells

Single cell preparation should be done within one hour after animal sacrifice (see note 6). The liver and the stomach will be processed as follows:

Liver: A portion of the left lateral lobe of the liver will be removed and washed in the cold mincing buffer until as much blood as possible has been removed (see note 7). The portion will be minced with a pair of fine scissors to release the cells. The cell suspension will be stored on ice for 15-30 seconds to allow large clumps to settle (or, the cell suspension will be strained through a Cell Strainer to remove lumps and the remaining suspension will be placed on ice), and the supernatant will be used to prepare comet slides.

Stomach: The stomach will be cut open and washed free from food using cold mincing buffer. The forestomach will be removed and discarded. The glandular stomach will be then placed into cold mincing buffer and incubated on ice for from 15 to 30 minutes. After incubation, the surface epithelia will be gently scraped two times using the a scalpel blade or a Teflon scrapper. This layer will be discarded and the gastric mucosa rinsed with the cold mincing buffer. The stomach epithelia will be carefully scraped 4-5 times (or more, if necessary) with a scalpel blade or Teflon scrapper to release the cells. The cell suspension will be stored on ice for 15-30 seconds to allow large clumps to settle (or, the cell suspension will be strained with a Cell Strainer to remove clumps and the remaining suspension will be placed on ice), and samples of the supernatant used to prepare comet slides.

1.4.6. Slide preparation

Slide preparation should be done within one hour after single cell preparation (see note 6). Comet slides will be prepared using laboratory specific procedures. The volume of the cell suspension added to 0.50% low melting agarose to make the slides will not decrease the percentage of low melting agarose by more than 10% (i.e., not below 0.45%) .

1.4.7. Lysis

Once prepared, the slides will be immersed in chilled lysing solution overnight in a refrigerator under a light proof condition (see note 6). After this incubation period, the slides will be rinsed in purified water or neutralization solution to remove residual detergent and salts prior to the alkali unwinding step.

1.4.8. Unwinding and electrophoresis

Slides will be randomly placed onto a platform of submarine-type electrophoresis unit

and the electrophoresis solution added. A balanced design will be used (see note 8). The electrophoresis solution will be poured until the surfaces of the slides are completely covered with the solution. The slides will be left to be unwind for 20 minutes. Next, the slides will be electrophoresed at 0.7 V/cm for at least 20 minutes, with a constant voltage at approximately 300 mA (see note 9). The current at the start and end of the electrophoresis period should be recorded. The temperature of the electrophoresis solution through unwinding and electrophoresis should be maintained at a constant temperature <10°C . The temperature of the electrophoresis solution at the start of unwinding, the start of electrophoresis, and the end of electrophoresis should be recorded.

1.4.9. Neutralization and dehydration of slides

After completion of electrophoresis, the slides will be immersed in the neutralization buffer for at least 5 minutes. All slides will be dehydrated by immersion into absolute ethanol (≥99.6%) for at least 5 minutes if slides will not be scored soon, allowed to air dry, and then stored until scored at room temperature, protected from humidity > 60 %. Once scored, slides should be retained and stored under low humidity conditions (e.g., in a desiccator) for potential rescoring.

1.4.10. DNA staining, comet visualization and analysis

Coded slides will be blind scored according to laboratory specific SOPs. The slides will be stained with SYBR Gold according to manufacturer's specifications. The comets will be measured via a digital (e.g. CCD) camera linked to an image analyzer system using a fluorescence microscope at magnification of 200X. For each sample (animal/tissue), fifty comets per slide will be analyzed, with 2 slides scored per sample (see note 10). Approximately 10 areas/slide should be observed at 5 cells or less/field (see note 11), taking care to avoid any selection bias, overlap counting of cells, and edge areas of slides. Heavily damaged cells exhibiting a microscopic image (commonly referred to as hedgehogs) consisting of small or non-existent head and large, diffuse tails will be excluded from data collection if the image analysis system can not properly score them (see note 12). However, the frequency of such comets should be determined per sample, based on the visual scoring of 100 cells per sample. The comet endpoints collected will be % tail DNA, tail length in microns measured from the estimated edge of the head region closest to the anode (see note 13), and, if possible for a particular image analysis system, Olive tail moment [= a measure of tail length (a distance between a center of head mass and a center of tail mass; microns) X a measure of DNA in tail (% tail DNA/100): Olive et al., 1990]. (see note 14)

1.4.11. Histopathology

When a positive Comet assay response is obtained for a tissue, a sample histopathological assessment will be conducted to evaluate for the presence of apoptotic and/or necrotic cells according to the SOP in each testing facility.

2. STATISTICS

Different approaches for data analysis have been proposed for comet data generated across a range of test substance dose levels (Lovell et al. 1999; Hartmann et al. 2003; Wiklund and Agurell 2003). The primary endpoint of interest for DNA migration is the % tail DNA. In addition, the distribution of migration patterns among cells within an animal will be considered. The percentage of "hedgehogs" will also be evaluated as a function of treatment. The unit of analysis for a specific tissue is the individual animal.

In data analysis process of this validation study, three conceptual key terms, i.e. "Endpoint", "Estimate", and "Effect" are defined and used. Briefly, "Endpoint" is defined as individual observed values for a parameter such as % DNA in tail. "Estimate" is defined as a mean calculated with values of a particular "Endpoint" in each animal. "Effect" is defined as difference of an average of "Estimate" between a negative control group and a treatment group (see note 15). Dunnett's test (two-sided, $P<0.05$) and linear Trend test (two-sided, $P<0.05$) will be applied to "Effect" to judge positive or negative as assay results. For the positive control group, Student's t-test (one-sided, $P<0.025$) will be applied to the "Effect".

3. DATA AND REPORTING

3.1.1. Treatment of results

Individual animal data and group summaries will be presented in a fixed tabular form that will be provided from the VMT.

3.1.2. Evaluation and interpretation of results

A positive response is defined as a statistically significant change in the % tail DNA in at least one dose group in comparison with the vehicle control value using Dunnett's test (two-sided, $P<0.05$) as well as a statistically significant linear Trend test (two-sided, $P<0.05$). A negative response is defined as the statistically nonsignificant change in both Dunnett's test and the linear Trend test, and an equivocal response is defined as the statistically significant change in either of Dunnett's test or the linear Trend test. The

positive control should produce a statistically significant increase in Student's t-test (one-sided, $P<0.025$), and if not, the study data will not be acceptable. Where a positive response is obtained in a test substance group, the investigator(s) will assess the possibility that a cytotoxic rather than a genotoxic effect is responsible based on the percentage of "hedgehogs" and histopathology (see note 16). Positive results indicate that the test substance induce DNA damage in the target tissue(s) investigated. Negative results indicate that, under the test conditions used, the test substance does not induce DNA damage *in vivo* in the tissue(s) evaluated.

3.1.3. Study report

The study report from each testing facility will at least include the following information:

3.1.3.1. Test substance and positive/negative controls

Identification; Chemical Abstracts Service Registry number (when available); supplier, lot number and purity (when available); physiochemical properties relevant to the conduct of the study, if known; justification for choice of vehicle; and solubility and stability of the substances in the solvent/vehicle, if known.

3.1.3.2. Test animals

Species/strain used; number, age and sex of animals; source, housing conditions, quarantine and acclimation procedure, and animal identification and group assignment procedure; individual weight of the animals on the day of receipt, at the end of the acclimation period, and before administration (at the time of grouping), including body weight range, mean and standard deviation for each group; and choice of tissue(s) and justification.

3.1.3.3. Reagents to prepare reagent solutions

Identification; supplier; lot number; and time limit for usage if known.

3.1.3.4. Test conditions

Data from range-finding study, if conducted; rationale for dose level selection; details of test substance preparation; details of the administration of the test substance; methods for verifying that the test substance reached the general circulation or target tissue, if applicable; details of food and water quality; detailed description of treatment and sampling schedules; method of measurement of toxicity, including histopathology; detailed methods of single cell preparation; method of slide preparation, including duration between tissue sampling and slide preparation, agarose concentration, lysis conditions (duration for lysis, etc.), alkali conditions and pH, alkali unwinding time and